Background

Targeting the immune system and the use of personalised vaccines for cancer therapy is a growing field. Tumour associated antigens and neoantigens have gained growing interest for the development of personalised therapeutic cancer vaccines, enabling the specific targeting of tumour cells in individual patients. The neoantigen cancer vaccine market size in 2024 is relatively small and is currently estimated to be US$ 48.7 million. However, this market is expected to grow enormously in the next few years and is expected to have a market size of ~ US$ 1.3 billion by 2030 (predicted CAGR of 73.4%). Although over 100 tumour-specific neoantigens are in clinical trials, their application is still limited due to various challenges, including inadequate strategies to target